Publication Name	World Journal of Diabetes
Manuscript ID	74740
Country	Taiwan

Received	2022-01-14 08:11
Peer-Review Started	2022-01-14 08:12
To Make the First Decision
Return for Revision	2022-04-18 00:27
Revised	2022-04-18 15:00
Second Decision	2022-05-23 03:28
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-05-28 07:03
Articles in Press	2022-05-28 07:03
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-05-31 07:38
Publish the Manuscript Online	2022-06-08 02:31

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Retrospective Study
Article Title	Immediate-release tofacitinib reduces insulin resistance in non-diabetic active rheumatoid arthritis patients: A single-center retrospective study
Manuscript Source	Invited Manuscript
All Author List	Chrong-Reen Wang and Hung-Wen Tsai
ORCID	Author(s) ORCID Number Chrong-Reen Wang http://orcid.org/0000-0001-9881-7024 Hung-Wen Tsai http://orcid.org/0000-0001-9223-2535
Funding Agency and Grant Number
Corresponding Author	Chrong-Reen Wang, MD, PhD, Full Professor, Department of Internal Medicine, National Cheng Kung University Hospital, No. 138 Sheng-Li Road, Tainan 70403, Taiwan. wangcr@mail.ncku.edu.tw
Key Words	Insulin resistance; Rheumatoid arthritis; Diabetes mellitus; Tofacitinib; Janus kinase inhibitor
Core Tip	An increased risk of insulin resistance (IR) has been identified in rheumatoid arthritis (RA), a chronic inflammatory disorder with elevated levels of pathogenic cytokines. In addition to controlling RA activity, biologics targeting proinflammatory cytokines have been shown to reduce IR, while it remains to be elucidated whether Janus kinase inhibitor therapy can cause IR reduction in such patients. This retrospective study carried out in non-diabetic active RA patients classified into high-IR and low-IR groups before tofacitinib (TOF) therapy demonstrated reduced IR by 24 wk of TOF treatment in the active RA patients with high baseline IR status.
Publish Date	2022-06-08 02:31
Citation	Wang CR, Tsai HW. Immediate-release tofacitinib reduces insulin resistance in non-diabetic active rheumatoid arthritis patients: A single-center retrospective study. World J Diabetes 2022; 13(6): 454-465
URL	https://www.wjgnet.com/1948-9358/full/v13/i6/454.htm
DOI	https://dx.doi.org/10.4239/wjd.v13.i6.454

Full Article (PDF)	WJD-13-454.pdf
Full Article (Word)	WJD-13-454.docx
Manuscript File	74740_Auto_Edited-LS.docx
Answering Reviewers	74740-Answering reviewers.pdf
Audio Core Tip	74740-Audio core tip.mp3
Biostatistics Review Certificate	74740-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	74740-Conflict-of-interest statement.pdf
Copyright License Agreement	74740-Copyright license agreement.pdf
Institutional Review Board Approval Form or Document	74740-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	74740-Language certificate.pdf
Peer-review Report	74740-Peer-review(s).pdf
Scientific Misconduct Check	74740-Bing-Fan JR-2.png
Scientific Editor Work List	74740-Scientific editor work list.pdf